Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXT007 versus factor VIII prophylaxis in hemophilia A without inhibitors
2025-522434-32-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Jul 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of zemocimig in hemophilia A (2 arms), sponsored by Roche. Primary endpoint: Annualized number of treated bleeds. Planned start Jul 2026; status: authorised.
02
Drugs
zemocimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2025-522434-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522434-32-00.